The arguments about the use of PSA screening and the like should also be viewed in actual mortality changes. In a recent paper in Nature Prostate Cancer the authors note:
During the last 30 years, there has been a major shift in initial
staging in prostate cancer (CaP) in Western countries, with the
incidence of metastases at diagnosis decreasing from over 50% in the 1970s to currently less than 10%.
Yet, CaP is still the second cause of cancer death in men. We used two
monthly curated databases of patients with castration-resistant prostate
cancer (CRPC) to describe the natural history of patients dying of CaP
in the modern era. In the modern era, approximately half of the patients who die from CaP
have metastases at diagnosis. The paradigm of progression from localized
disease to metastasis and eventually death is only represented in the
other half, although possible initial screening and staging errors ought
to be taken into consideration. More efforts are needed to conduct
trials in patients with newly diagnosed metastatic Ca.
Thus the conclusion should be clear; early detection, no matter what the discomfort, should be the goal.